ICAM1 and neoplasm: Importantly, the positive effects of SeGP65 were also maintained in mice with mature tumors, i.e., 3 weeks of tumor growth, when ICAM-1 mRNA levels were still elevated within most treatment groups and SeGP65 fed mice alone showed no change with tumor cell infusion.